Have a feature idea you'd love to see implemented?
Let us know!
IDYA IDEAYA Biosciences Inc
Price (delayed)
$26.6
Market cap
$2.3B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.33
Enterprise value
$1.92B
IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates
Highlights
IDEAYA Biosciences's equity has surged by 132% YoY and by 27% QoQ
The quick ratio has increased by 31% from the previous quarter and by 18% YoY
The company's gross profit has shrunk by 83% YoY and by 67% QoQ
The revenue has dropped by 83% year-on-year and by 67% since the previous quarter
Key stats
What are the main financial stats of IDYA
Market
Valuations
Earnings
Shares outstanding
86.43M
Market cap
$2.3B
Enterprise value
$1.92B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.9
Price to sales (P/S)
584.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
488.7
Revenue
$3.92M
EBIT
-$178.12M
EBITDA
-$173.91M
Free cash flow
-$153.27M
Per share
Balance sheet
Liquidity
EPS
-$2.33
Free cash flow per share
-$1.78
Book value per share
$13.97
Revenue per share
$0.05
TBVPS
$14.39
Total assets
$1.24B
Total liabilities
$59.46M
Debt
$18.8M
Equity
$1.18B
Working capital
$891.56M
Debt to equity
0.02
Current ratio
22.93
Quick ratio
22.65
Net debt/EBITDA
2.2
Margins
Efficiency
Dividend
EBITDA margin
-4,434.1%
Gross margin
100%
Net margin
-4,541.6%
Operating margin
-5,730.6%
Return on assets
-18.6%
Return on equity
-19.4%
Return on invested capital
-24.9%
Return on capital employed
-14.9%
Return on sales
-4,541.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IDYA stock price
How has the IDEAYA Biosciences stock price performed over time
Intraday
4.15%
1 week
-9.74%
1 month
-13.86%
1 year
-12.79%
YTD
-25.24%
QTD
-16.04%
Financial performance
How have IDEAYA Biosciences's revenue and profit performed over time
Revenue
$3.92M
Gross profit
$3.92M
Operating income
-$224.75M
Net income
-$178.12M
Gross margin
100%
Net margin
-4,541.6%
IDYA's operating income has dropped by 89% year-on-year and by 17% since the previous quarter
The company's gross profit has shrunk by 83% YoY and by 67% QoQ
The revenue has dropped by 83% year-on-year and by 67% since the previous quarter
The net income has plunged by 73% YoY and by 16% from the previous quarter
Growth
What is IDEAYA Biosciences's growth rate over time
Valuation
What is IDEAYA Biosciences stock price valuation
P/E
N/A
P/B
1.9
P/S
584.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
488.7
The EPS has declined by 17% year-on-year and by 6% since the previous quarter
IDEAYA Biosciences's equity has surged by 132% YoY and by 27% QoQ
The stock's P/B is 39% below its last 4 quarters average of 3.1 and 21% below its 5-year quarterly average of 2.4
The stock's price to sales (P/S) is 91% more than its last 4 quarters average of 306.3
The revenue has dropped by 83% year-on-year and by 67% since the previous quarter
Efficiency
How efficient is IDEAYA Biosciences business performance
The company's return on equity rose by 20% YoY and by 5% QoQ
IDYA's ROIC is up by 20% YoY and by 2.7% from the previous quarter
The ROA has grown by 18% YoY and by 6% from the previous quarter
Dividends
What is IDYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IDYA.
Financial health
How did IDEAYA Biosciences financials performed over time
IDEAYA Biosciences's total liabilities has soared by 139% YoY and by 42% from the previous quarter
IDEAYA Biosciences's total assets has surged by 133% YoY and by 27% QoQ
The company's debt is 98% lower than its equity
IDEAYA Biosciences's equity has surged by 132% YoY and by 27% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.